International Journal of Clinical Pharmacy

, Volume 35, Issue 1, pp 79–86

Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial

  • Aline Oliveira Magalhães Mourão
  • Wandiclécia Rodrigues Ferreira
  • Maria Auxiliadora Parreiras Martins
  • Adriano Max Moreira Reis
  • Maria Ruth Gaede Carrillo
  • Andrea Grabe Guimarães
  • Lisiane Silveira Ev
Research Article

DOI: 10.1007/s11096-012-9710-7

Cite this article as:
Mourão, A.O.M., Ferreira, W.R., Martins, M.A.P. et al. Int J Clin Pharm (2013) 35: 79. doi:10.1007/s11096-012-9710-7

Abstract

Background Brazilians with type 2 diabetes require action to improve haemoglobin A1C levels considering the fact that approximately 73 % of them have poor glycaemic control. Evidence has shown the potential benefits of pharmaceutical care programs in type 2 diabetes patients. Objective To evaluate the effect of a pharmaceutical care program on blood glucose, blood pressure and lipid profile in hyperglycaemic patients undergoing drug treatment for type 2 diabetes. Setting Six primary care units of the Brazilian public health system, Ouro Preto, Brazil. Method An open, randomised, controlled clinical trial was conducted for 6 months. Subjects aged 18 years or older who were using oral antidiabetic medications and presenting haemoglobin A1C levels ≥7 % were randomly assigned to receive only usual health care or usual health care plus pharmaceutical intervention. Main outcome measure Haemoglobin A1C. Results A total of 129 subjects were enrolled, and 100 patients completed the study. Compared to the control group (n = 50), the intervention group (n = 50) showed a significant reduction of haemoglobin A1C (−0.6 vs 0.7 %, p = 0.001), fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides and systolic blood pressure and a significant increase in HDL cholesterol and the use of lipid-modifying agents and platelet aggregation inhibitors. Conclusions This study suggests that a pharmaceutical care program may provide important contributions to reduce haemoglobin A1C in type 2 diabetes patients. Moreover, the promotion of the rational use of drugs may be better achieved in a context of pharmaceutical care programs in Brazil.

Keywords

BrazilDiabetes mellitusDiabetes type 2PharmacistsPharmaceutical careRandomised controlled trial

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Aline Oliveira Magalhães Mourão
    • 1
  • Wandiclécia Rodrigues Ferreira
    • 2
  • Maria Auxiliadora Parreiras Martins
    • 3
  • Adriano Max Moreira Reis
    • 3
  • Maria Ruth Gaede Carrillo
    • 4
  • Andrea Grabe Guimarães
    • 2
  • Lisiane Silveira Ev
    • 2
  1. 1.Post-Graduate Program in Pharmaceutical Sciences, School of PharmacyFederal University of Ouro PretoOuro PretoBrazil
  2. 2.Department of Pharmacy, School of PharmacyFederal University of Ouro PretoOuro PretoBrazil
  3. 3.Department of Pharmaceutical Products, School of PharmacyFederal University of Minas GeraisBelo HorizonteBrazil
  4. 4.Department of Clinical Analysis, School of PharmacyFederal University of Ouro PretoOuro PretoBrazil